AKBA - CIK 0001517022
The table below shows Akebia Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $67.99M | -$40.66M | -$23.38M | -$73.15M | -$252.97M | -$110.39M |
| Capital expenditure | $291.00K | $33.00K | $0.00 | $114.00K | $59.00K | $317.00K |
| Investing cash flow | -$7.93M | -$33.00K | $0.00 | -$114.00K | $39.94M | -$40.00M |
| Dividends paid | - | - | - | - | - |
Akebia Therapeutics, Inc. reported operating cash flow of $67.99M for fiscal year 2025. That is up 267.2% from -$40.66M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $57.91M (FY 2016) to $67.99M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $72.93M | $49.66M | -$25.21M | $14.60M | $133.73M | $231.72M |